Monash researchers have invented an antibody which can prevent the formation of bad clots, such as those in stroke and heart attack.
Heart attack and stroke remain the leading causes of mortality and morbidity worldwide. Current anti-thrombotic (anti-clotting) therapies can, and do, cause severe bleeding complications because they also interfere with normal blood clotting. Four out of five patients who receive antiplatelet therapy still have recurring cardiovascular events.
